What is MiLaboratories?
MiLaboratories is a recognized technology leader in the field of mammalian adaptive immune system profiling. For over a decade, the company has pioneered original technology for molecular barcoding utilizing unique molecular identifiers (UMIs). Coupled with a sophisticated suite of algorithms and software tools, MiLaboratories enables advanced analysis of T-cell and B-cell repertoires. Its flagship software, MiXCR, is widely regarded as the gold standard in immunosequencing, adopted by major global pharmaceutical companies, leading academic institutions, and sequencing hardware manufacturers. This deep expertise positions MiLaboratories at the forefront of immunological research and development.
How much funding has MiLaboratories raised?
MiLaboratories has raised a total of $12.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$10M
Angel/Seed (2022): $2.3M with participation from Acrobator Ventures and Speedinvest
Series A (2024): $10M led by Acrobator Ventures, Kfund, and Speedinvest
Key Investors in MiLaboratories
Acrobator Ventures
Acrobator Ventures is a pre/seed fund focused on early-stage startups, particularly those from the CIS, Baltics, and CEE regions aiming for international scaling. They invest in B2B, AI/ML software, cybersecurity, fintech, and data-heavy technologies, offering initial investments from $200k to $1.25m.
Speedinvest
Speedinvest is a venture capital fund with over €1B allocated for pre-Seed, Seed, and early-stage tech startups across Europe, focusing on Deep Tech, Fintech, Health Bio, Climate Tech, and SaaS Infra. They provide capital and hands-on support to accelerate startup growth.
Kfund
KFUND aims to provide fast, simple, and easily accessible funding solutions for companies.
What's next for MiLaboratories?
The substantial enterprise-level funding and recent strategic investment signal a strong trajectory for MiLaboratories. This capital injection is expected to fuel further technological advancements, expand market reach, and potentially accelerate the development of new applications for its immunosequencing technologies. The company is poised to leverage this financial backing to solidify its position as a key player in the rapidly evolving biotechnology and life sciences sectors, driving innovation in immune system analysis and therapeutic development.
See full MiLaboratories company page
